{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:36:14Z","timestamp":1790444174821,"version":"4.1.0"},"reference-count":102,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Allogeneic haematopoietic stem cell transplantation (HSCT) is indicated in children with high-risk, relapsed or refractory acute lymphoblastic leukaemia (ALL). HLA-matched grafts from cord blood and stem cell repositories have allowed patients without suitable sibling donors to undergo HSCT. However, challenges in procuring matched unrelated donor (MUD) grafts due to high cost, ethnic disparity and time constraints have led to the exponential rise in the use of stem cells from human leukocyte antigen (HLA)-haploidentical family donors. Whilst HLA-haploidentical HSCT (hHSCT) performed in adult patients with acute leukaemia has produced outcomes similar to MUD transplants, experience in children is limited. Over the last 5 years, more data have emerged on hHSCT in the childhood ALL setting, allowing comparisons with matched donor transplants. The feasibility of hHSCT using adult family donors in childhood ALL may also address the ethical issues related to selection of minor siblings in matched sibling donor transplants. Here, we review hHSCT in paediatric recipients with ALL and highlight the emergence of hHSCT as a promising therapeutic option for patients lacking a suitable matched donor. Recent issues related to conditioning regimens, donor selection and graft-vs.-host disease prophylaxis are discussed. We also identify areas for future research to address transplant-related complications and improve post-transplant disease-free survival.<\/jats:p>","DOI":"10.3389\/fped.2021.758680","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T08:41:34Z","timestamp":1642754494000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["HLA-Haploidentical Family Donors: The New Promise for Childhood Acute Lymphoblastic Leukaemia?"],"prefix":"10.3389","volume":"9","author":[{"given":"Syaza","family":"Ab Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Matic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Yordanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Ariffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41409-020-01014-x","article-title":"The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG","volume":"56","author":"Dalle","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/S0140-6736(07)60915-5","article-title":"Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study","volume":"369","author":"Eapen","year":"2007","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/sj.bmt.1705963","article-title":"Searching for alternative hematopoietic stem cell donors for pediatric patients","volume":"41","author":"Rocha","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1365-2141.2009.07828.x","article-title":"Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood","volume":"147","author":"Smith","year":"2009","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1038\/s41409-020-0826-4","article-title":"The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus","volume":"55","author":"Passweg","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4161\/chim.24070","article-title":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell-depletion for the treatment of hematologic diseases","volume":"4","author":"Huang","year":"2013","journal-title":"Chimerism"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.bbmt.2018.03.001","article-title":"Current allogeneic hematopoietic stem cell transplantation for pediatric acute lymphocytic leukemia: Success, failure and future perspectives-a single-center experience, 2008 to 2016","volume":"24","author":"Yanir","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.3389\/fimmu.2019.02769","article-title":"The evolution of T cell depleted haploidentical transplantation","volume":"10","author":"Aversa","year":"2019","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fimmu.2020.00191","article-title":"Key aspects of the immunobiology of haploidentical hematopoietic cell transplantation","volume":"11","author":"Baumeister","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/bloodadvances.2017006932","article-title":"HSC extrinsic sex-related and intrinsic autoimmune disease-related human B-cell variation is recapitulated in humanized mice","volume":"1","author":"Borsotti","year":"2017","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1172\/JCI3741","article-title":"CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses","volume":"102","author":"Blazar","year":"1998","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1172\/JCI85796","article-title":"Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality","volume":"126","author":"Saha","year":"2016","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1172\/JCI129965","article-title":"Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease","volume":"130","author":"Divito","year":"2020","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1172\/JCI133909","article-title":"Donor monocyte-derived macrophages promote human acute graft-versus-host disease","volume":"130","author":"Jardine","year":"2020","journal-title":"J Clin Invest"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.4049\/jimmunol.0903781","article-title":"Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO","volume":"184","author":"Booth","year":"2010","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse","volume":"124","author":"Martelli","year":"2014","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.coi.2017.11.003","article-title":"Natural killer cell education in human health and disease","volume":"50","author":"Boudreau","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fimmu.2017.00465","article-title":"Natural killer cells in graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"8","author":"Simonetta","year":"2017","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000445325","article-title":"Natural killer cells for therapy of leukemia","volume":"43","author":"Suck","year":"2016","journal-title":"Transfus Med Hemother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bcmd.2004.08.005","article-title":"Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation","volume":"33","author":"Ruggeri","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1182\/blood-2014-09-599993","article-title":"Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality","volume":"125","author":"Mancusi","year":"2015","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbmt.2017.11.042","article-title":"Killer cell immunoglobulin-like receptor-ligand mismatch in donor versus recipient direction provides better graft-versus-tumor effect in patients with hematologic malignancies undergoing allogeneic T cell-replete haploidentical transplantation followed by post-transplant cyclophosphamide","volume":"24","author":"Wanquet","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood.V84.11.3948.bloodjournal84113948","article-title":"Successful engraftment of T-cell-depleted haploidentical \u201cthree-loci\u201d incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum","volume":"84","author":"Aversa","year":"1994","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1182\/blood-2008-02-140095","article-title":"A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation","volume":"112","author":"Ciceri","year":"2008","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2018-07-861575","article-title":"Unrelated donor vs HLA-haploidentical alpha\/beta T-cell- and B-cell-depleted HSCT in children with acute leukemia","volume":"132","author":"Bertaina","year":"2018","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e13192","DOI":"10.1111\/petr.13192","article-title":"Comparison of outcomes after HLA-matched unrelated and alphabeta T-cell-depleted haploidentical hematopoietic stem cell transplantation for children with high-risk acute leukemia","volume":"22","author":"Erbey","year":"2018","journal-title":"Pediatr Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1038\/bmt.2015.87","article-title":"Improved immune recovery after transplantation of tcralphabeta\/CD19-depleted allografts from haploidentical donors in pediatric patients","author":"Lang","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood.V130.Suppl_1.214.214","article-title":"Safety and efficacy of tcralpha\/beta and CD19 depleted haploidentical stem cell transplantation following reduced intensity conditioning in children: results of a prospective multicenter phase I\/II clinical trial","volume":"130","author":"Lang","year":"2017","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1182\/blood.V128.22.4672.4672","article-title":"Tcr\u03b1\u03b2+\/CD19+-depletion in hematopoietic stem cells transplantation from matched unrelated and haploidentical donors following treosulfan or TBI-based conditioning in pediatric acute lymphoblastic leukemia patients","volume":"128","author":"Shelikhova","year":"2016","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"26839","DOI":"10.1002\/pbc.26839","article-title":"Comparison of two cytoreductive regimens for alphabeta-T-cell-depleted haploidentical HSCT in pediatric malignancies: Improved engraftment and outcome with TBI-based regimen","volume":"65","author":"Jacoby","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.bbmt.2016.02.002","article-title":"Feasibility and outcome of haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide for children and adolescents with hematologic malignancies: an AIEOP-GITMO retrospective multicenter study","volume":"22","author":"Berger","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.bbmt.2018.06.034","article-title":"Favorable outcome of post-transplantation cyclophosphamide haploidentical peripheral blood stem cell transplantation with targeted busulfan-based myeloablative conditioning using intensive pharmacokinetic monitoring in pediatric patients","volume":"24","author":"Hong","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3109\/08880018.2014.961214","article-title":"Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies","volume":"31","author":"Sawada","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.bbmt.2016.11.016","article-title":"Nonmyeloablative haploidentical bone marrow transplantation with post-transplantation cyclophosphamide for pediatric and young adult patients with high-risk hematologic malignancies","volume":"23","author":"Klein","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","first-page":"427.e1","DOI":"10.1016\/j.jtct.2021.02.010","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide in children with high-risk leukemia using a reduced-intensity conditioning regimen and peripheral blood as the stem cell source","volume":"27","author":"Trujillo","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41409-020-01063-2","article-title":"Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric patients affected by acute leukemia","volume":"56","author":"Saglio","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.bbmt.2015.11.010","article-title":"Haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in children with advanced acute leukemia with fludarabine-, busulfan-, and melphalan-based conditioning","volume":"22","author":"Jaiswal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","article-title":"Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults","volume":"4","author":"Symons","year":"2020","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e13546","DOI":"10.1111\/petr.13546","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide in high-risk children: A single-center study","volume":"23","author":"Uygun","year":"2019","journal-title":"Pediatr Transplant"},{"key":"B43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/petr.12658","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide in high-risk children: A single-center study","volume":"20","author":"Yesilipek","year":"2016","journal-title":"Pediatr Transplant"},{"key":"B44","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fped.2020.00282","article-title":"T-Cell replete myeloablative haploidentical bone marrow transplantation is an effective option for pediatric and young adult patients with high-risk hematologic malignancies","volume":"8","author":"Katsanis","year":"2020","journal-title":"Front Pediatr"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e1033","DOI":"10.1097\/MPH.0000000000002030","article-title":"Haploidentical stem cell transplantation with posttransplant cyclophosphamide for pediatric acute leukemia is safe and effective","volume":"43","author":"Sharma","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"424.e1","DOI":"10.1016\/j.jtct.2021.01.016","article-title":"Outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with acute lymphoblastic leukemia","volume":"27","author":"Ruggeri","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.bbmt.2018.01.031","article-title":"A modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter study","volume":"24","author":"Chiusolo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1016\/j.bbmt.2020.08.010","article-title":"Does post-transplantation cyclophosphamide inhibit graft-versus-leukemia?","volume":"10","author":"Fuchs","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","article-title":"Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the acute leukemia working party of the European Society for Blood and Marrow Transplantation","volume":"26","author":"Ruggeri","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.bbmt.2008.02.007","article-title":"Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children","volume":"14","author":"Liu","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/bmt.2013.99","article-title":"Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia","volume":"48","author":"Liu","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B53","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","article-title":"Who is the best donor for a related HLA haplotype-mismatched transplant?","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/ijc.30249","article-title":"Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia","volume":"139","author":"Mo","year":"2016","journal-title":"Int J Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.bbmt.2018.12.007","article-title":"Allogeneic hematopoietic stem cell transplantation, especially haploidentical, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era","volume":"25","author":"Xue","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/bjh.16226","article-title":"Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk Philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission","volume":"188","author":"Xue","year":"2020","journal-title":"Br J Haematol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/sj.bmt.1705046","article-title":"Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies","volume":"36","author":"Ji","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"B58","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1182\/blood-2012-08-453399","article-title":"Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies","volume":"121","author":"Di Bartolomeo","year":"2013","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.2016.151779","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant","volume":"102","author":"Ruggeri","year":"2017","journal-title":"Haematologica"},{"key":"B61","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11427-019-9594-7","article-title":"Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF\/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)","volume":"63","author":"Tang","year":"2020","journal-title":"Sci China Life Sci"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/bmt.2016.161","article-title":"Ex vivo T-cell depletion and post-transplant cyclophosphamide: 10 years of experience at a single center","volume":"51","author":"Dufort","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B63","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ajh.25661","article-title":"Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH)","volume":"95","author":"Perez-Martinez","year":"2020","journal-title":"Am J Hematol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41409-021-01246-5","article-title":"Contemporary haploidentical stem cell transplant strategies in children with hematological malignancies","volume":"56","author":"Shah","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbmt.2015.11.001","article-title":"Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States","volume":"22","author":"Apperley","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B66","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bbmt.2015.09.002","article-title":"Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index","volume":"22","author":"Bashey","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B67","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","article-title":"Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome","volume":"16","author":"Kasamon","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B68","doi-asserted-by":"publisher","first-page":"644","DOI":"10.4049\/jimmunol.172.1.644","article-title":"Determinants of antileukemia effects of allogeneic NK cells","volume":"172","author":"Leung","year":"2004","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/s41409-019-0543-z","article-title":"Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL","volume":"54","author":"Babor","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B70","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1182\/blood-2014-03-565069","article-title":"KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL","volume":"124","author":"Oevermann","year":"2014","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.leukres.2017.03.001","article-title":"Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors","volume":"57","author":"Gonzalez-Vicent","year":"2017","journal-title":"Leuk Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1182\/blood-2008-01-135285","article-title":"Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor","volume":"112","author":"Stern","year":"2008","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41409-019-0499-z","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation","volume":"55","author":"Ciurea","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B74","year":"2021","journal-title":"International Standards for Hematopoietic Cellular Therapy Production Collection, Processing, and Administration. Eighth ed"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bbmt.2018.02.005","article-title":"Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors","volume":"24","author":"Elmariah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B76","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/bmt.2013.223","article-title":"HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies","volume":"49","author":"Zhang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/bmt.2017.60","article-title":"Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier","volume":"52","author":"Garnier","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B78","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/MOH.0000000000000116","article-title":"Novel strategies to prevent relapse after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes","volume":"22","author":"Kekre","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"6006","DOI":"10.1182\/blood-2011-07-338822","article-title":"Haploidentical hematopoietic transplantation: current status and future perspectives","volume":"118","author":"Reisner","year":"2011","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.20.01801","article-title":"Graft versus leukemia: current status and future perspectives","volume":"39","author":"O'Neill","year":"2021","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fimmu.2020.00147","article-title":"Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation","volume":"11","author":"Rovatti","year":"2020","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1182\/bloodadvances.2019000389","article-title":"Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute","volume":"4","author":"Soiffer","year":"2020","journal-title":"Blood Adv"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/cncr.30130","article-title":"Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/asheducation-2017.1.708","article-title":"Cells to prevent\/treat relapse following allogeneic stem cell transplantation","volume":"2017","author":"Dietz","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B87","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2217\/imt.13.31","article-title":"Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies","volume":"5","author":"El-Jurdi","year":"2013","journal-title":"Immunotherapy"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant chimeric antigen receptor therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-018-0593-5","article-title":"CD19 CAR-T cell therapy for relapsed\/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies","volume":"11","author":"Zhang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukaemia remission by CD19 CAR T-cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40364-020-00247-8","article-title":"Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia: who? When? Why?","volume":"8","author":"Jiang","year":"2020","journal-title":"Biomark Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e16498","DOI":"10.1097\/MD.0000000000016498","article-title":"Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two cases report","volume":"98","author":"Zhang","year":"2019","journal-title":"Medicine"},{"key":"B96","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1182\/blood-2016-06-724005","article-title":"Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution","volume":"128","author":"de Koning","year":"2016","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1182\/blood-2014-01-551671","article-title":"Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-07-730564","article-title":"Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation","volume":"128","author":"Mancusi","year":"2016","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.758680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T08:41:37Z","timestamp":1642754497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.758680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":102,"alternative-id":["10.3389\/fped.2021.758680"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.758680","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"article-number":"758680"}}